NASDAQ · Key Statistics

Cytosorbents Corporation (CTSO) P/E Ratio, ROE & Key Statistics

$4.52 NASDAQ: CTSO Market Cap $14.24M

Data as of Nov 17, 2026 close · Source: Financial Modeling Prep (methodology)

Every valuation, profitability, balance-sheet and per-share figure DeltaScreener holds for Cytosorbents Corporation (CTSO), each with what it measures. Figures are trailing twelve months or the most recent reported period.

Valuation

MetricValue
P/E ratioShare price divided by earnings per share.-0.91
P/B ratioShare price divided by book value per share.-6.64
P/S ratioMarket value divided by annual revenue.0.41
PEG ratioP/E divided by the earnings growth rate.0.01
EV / EBITDAEnterprise value against earnings before interest, tax, depreciation and amortisation.-3.38
EV / RevenueEnterprise value against annual revenue.1.09
Earnings yieldEarnings per share as a percentage of the share price — the inverse of P/E.-109.89%
Free cash flow yieldFree cash flow as a percentage of market value.-52.90%
Price / free cash flowMarket value divided by free cash flow.-1.89

Profitability

MetricValue
Gross marginRevenue left after the direct cost of goods sold.72.91%
Operating marginRevenue left after operating costs.-28.63%
Net marginRevenue left after every cost, including tax and interest.-45.05%
Return on equityProfit as a percentage of shareholders’ equity.-133.33%
Return on assetsProfit as a percentage of total assets.-45.42%
Return on capital employedOperating profit against the capital the business uses.-117.49%

Financial health

MetricValue
Current ratioCurrent assets divided by current liabilities. Above 1 means short-term assets cover short-term bills.0.55
Quick ratioThe same, excluding inventory.0.44
Cash ratioCash alone against current liabilities.0.60
Debt to equityTotal borrowings against shareholders’ equity.-12.81
Debt to assetsTotal borrowings against total assets.0.66
Interest coverageHow many times operating profit covers the interest bill.-6.50

Per share and size

MetricValue
Earnings per shareProfit attributable to each share.−$2.60
Book value per shareShareholders’ equity divided by shares outstanding.−$0.73
Market capitalisationShare price times shares outstanding.$14.24M
Enterprise valueMarket value plus net debt — what it would cost to buy the business outright.$41.35M
EmployeesReported headcount.149

Dividend

MetricValue
Dividend yieldAnnual dividend as a percentage of the share price.0.00%

Cytosorbents Corporation (CTSO) statistics — frequently asked questions

What is Cytosorbents Corporation's P/E ratio?

Cytosorbents Corporation (CTSO) trades on a price-to-earnings ratio of -0.91. A negative P/E means the company reported a loss, so the ratio is not a meaningful valuation measure.

What is Cytosorbents Corporation's return on equity?

Cytosorbents Corporation (CTSO) reports a return on equity of -133.33%, meaning it generated that much profit for every dollar of shareholders' equity.

How much debt does Cytosorbents Corporation carry?

Cytosorbents Corporation (CTSO) has a debt-to-equity ratio of -12.81, which compares total borrowings with shareholders' equity.

What is Cytosorbents Corporation's profit margin?

Cytosorbents Corporation (CTSO) keeps -45.05% of revenue as net profit after every cost, including tax and interest.

P/E and ROE of other Medical - Devices stocks

ABT P/E 38.41ISRG P/E 54.04MDT P/E 23.33SYK P/E 31.57BSX P/E 18.42EW P/E 59.08RMD P/E 20.92DXCM P/E 30.09PHG P/E 26.93ZBH P/E 26.95All Medical - Devices stocks

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)Eli Lilly (LLY)JPMorgan (JPM)

Related stock screens

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksHigh ROE StocksLow P/E StocksHigh Net Margin StocksDividend StocksLow Debt StocksNasdaq High ROE StocksAll stock screens

Data for information only, not investment advice. Figures may be delayed or inaccurate; verify against company filings. See our disclaimer.